![]() The potentially harmful effects of rapid drug withdrawal may have made the placebo group appear artificially prone to relapse - the key finding that made Abilify appear beneficial, Tsai and his colleagues say. What's more, the study population was limited to people whose mood had already stabilized on Abilify during the preliminary phase of the trial, and the placebo group therefore consisted of patients who were abruptly switched from Abilify to placebo. ![]() The first phase of the trial lasted for 26 weeks, and less than one-fifth of the participants went on to complete the 48-week follow-up phase. For one, they say, it may have been too short to judge the drug's true effectiveness in preventing mood swings over the long term. That trial had several important limitations, according to Tsai and his coauthors. The trial was funded jointly by Otsuka Pharmaceutical Co., the Japanese company that developed Abilify, and Bristol-Myers Squibb, which markets the drug in the U.S. Their search turned up just one clinical trial, data from which was used in two published studies. : Bipolar celebrities: does it make them more creative? Studies of that design are considered the gold standard of medical research. "But it's certainly worth talking to your doctor about how it's working for you."Īfter noticing that a growing number of patients seemed to be asking for Abilify by name, Tsai and his colleagues performed an in-depth search of double-blind, randomized controlled trials - both published and unpublished - on the use of Abilify for the long-term treatment of bipolar disorder. "It may actually be working for some people," he says. Tsai emphasizes that individuals taking Abilify for bipolar disorder should not abruptly stop the medication. ![]() "We failed to find sufficient data to support its use." Tsai, M.D., one of the lead authors of the review and a visiting researcher at Harvard University. The medical research does not appear to justify the widespread use of Abilify for maintenance therapy, says psychiatrist Alexander C. And a 2008 survey of doctors found that it had become the first-choice drug for bipolar maintenance therapy among 23% of psychiatrists and 16% of primary care physicians. Since then Abilify sales have more than doubled, according to market research cited in the review. In 2005, the Food and Drug Administration also approved it for long-term use in bipolar patients whose moods have stabilized (known as "maintenance" therapy). The drug, Abilify (aripiprazole), was initially used to treat schizophrenia and acute episodes of mania, the better-than-good feeling that characterizes bipolar disorder. The team also discussed the rest of the wide variety within our portfolio with potential buyers by utilizing our new Post Press and Packaging Brochures.() - The growing use of a popular drug in the long-term treatment of bipolar disorder is based largely on a single, flawed clinical trial that may be steering doctors and patients away from drugs with a more established track record, a new review published this week in the journal "PLoS Medicine" suggests. The team had an excellent experience and were grateful to be able to connect with both attendees and and other exhibitors.īest Graphics had a booth to showcase an Ecosystem Best 76 Film Laminator with 800° rotating Hot Knife Film Separation technology. Attendees were given the opportunity to view equipment demonstrations, interact with top brands, and network with industry leaders.įive members of the Best Graphics team - Dan Brahm, AJ Brahm, Daries French, Jeff Weis, and John Hower - traveled over to represent the company at the event. ![]() The purpose of Amplify is to display the brands, products, and processes that are currently raising the standard for foiling, coating, diecutting, folding and gluing, binding, etc. The event took place from June 14 th to the 16 th in Minneapolis, Minnesota. Best Graphics (Waukesha, WI) recently sponsored and was an exhibitor at Amplify 2022, a print finishing and embellishment event.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |